Bioconjugates

Vaccine
#AstraZeneca #Bioconjugates #Immunology / Virology & Vaccines #Mergers and acquisitions

AstraZeneca buys conjugate vaccine developer Omniose

Omniose is to be acquired by AstraZeneca, following a productive three-year exclusive research collaboration between the two companies.  Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit.   The acquisition brings Omniose’s… Read More

#Business & Investment #News

Avidity Biosciences HQ
#Antibodies #Avidity Biosciences #Bioconjugates #Mergers and acquisitions #Novartis #Oligonucleotides

Novartis acquires Avidity Biosciences for $12 billion

Novartis has entered into a definitive merger agreement with antibody oligonucleotide conjugates (AOCs) developer Avidity Biosciences.   The acquisition will follow the separation of Avidity’s early-stage precision cardiology programmes into SpinCo, which is expected to be a publicly traded company.   SpinCo will be led by Kathleen… Read More

#Business & Investment #News